Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will GSK-Hanmi Deal Trigger Similar Tie-ups With Korean Pharmas?

This article was originally published in PharmAsia News

Executive Summary

Korea’s Hanmi Pharmaceutical is positioning itself as a partner of choice for reformulations and fixed-dose combinations after inking its second major deal with a multinational.

Advertisement

Related Content

Korea's Hanmi And Merck in Discussion to Sell Hanmi's Hypertension Drug In Other Countries including Six Asia-Pacific Countries
GSK Expands In Korea With Purchase Of 9.9 Percent Equity Stake In Dong-A Pharma

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC080962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel